Methamphetamine (meth) addiction is a costly burden to both the individual user and society as a whole. Establishing effective pharmacotherapies to treat meth dependence is needed to help solve this health problem. The study reported herein examined the effects of varenicline, a partial ␣4␤2 and full ␣7 nicotinic acetylcholine receptor agonist, on meth self-administration and reinstatement in male SpragueDawley rats. Following indwelling jugular catheter surgery, rats were either trained to self-administer meth or saline on a variable ratio (VR) 3 schedule of reinforcement. Self-administration sessions (2 h duration; 19 total sessions) were conducted daily. The effect of varenicline pretreatment on meth and saline self-administration was then determined using a within-study design. All rats received varenicline (0.0, 0.3, 1.0, and 3.0 mg/kg) prior to 4 different test sessions. Dose order was randomly assigned and each test was separated by 2 standard self-administration sessions to assess stability of responding. Fifteen extinction sessions (no meth available) followed the last test. Extinction was followed by meth-primed (0.3 mg/kg IP) reinstatement tests to examine the effect of varenicline on meth-seeking behavior. All rats again received all doses of varenicline over 4 separate reinstatement tests performed on 4 consecutive days. Varenicline did not alter self-administration of meth or saline. Additionally, the 0.3 and 1.0 doses of varenicline non-specifically increased active lever responding during the reinstatement test sessions. This latter finding suggests that varenicline may increase relapse liability and should not be utilized as pharmacotherapy to treat meth dependence.
Introduction
Establishing more efficacious methamphetamine (meth) cessation treatments is vital to decreasing the deleterious health effects to the individual and lowering the exorbitant economic and societal cost of meth. Pharmacotherapies that correct dopaminergic hypofunction during meth abstinence have been identified as possible meth-cessation medications [7, 15, 20] . Nicotinic acetylcholine receptors (nAChRs) can modulate dopamine release [10] . In fact, medications that effectively increase acetylcholine by inhibiting acetylcholinesterase reduce the positive subjective effects of meth [6, 8, 7] . Additionally, varenicline (Chantix ® ), a partial ␣4␤2 and full ␣7 nicotinic acetylcholine receptor agonist, [5, 16] can reduce the positive subjective effects of meth in humans, an effect that ଝ This work was supported by the National Institutes of Health research grant DA034389. * Corresponding author.
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may reflect nAChR agonism reversing dopaminergic hypofunction [23, 25] . A reduction in the positive subjective effects of meth by varenicline points to the possible use of varenicline to treat meth dependence [23, 25] . However, research in preclinical models has raised some concerns with this premise, at least in females. Pittenger et al. [18] examined the effects of varenicline on meth self-administration and meth-primed reinstatement in female rats. While varenicline reduced meth self-administration in that study, the reduction was not specific to meth (i.e., responding was also reduced in rats that received saline and timeout cues). Notably, varenicline treatment increased drug-seeking in methprimed reinstatement tests. This increase in drug-seeking suggests that varenicline may in fact serve to increase relapse in females. Whether or not this increase in reinstatement and non-specific decrease in self-administration responding generalizes to male rats is the focus of this brief report. 
Materials and methods

Subjects
Fifteen male Sprague-Dawley rats were purchased from Harlan Laboratories Inc. (Indianapolis, IN, USA) at approximately 9 weeks of age. Rats were individually housed with ad libitum access to water in polycarbonate cages (35.5 × 32 × 18; length × width × depth) lined with TEK-Fresh ® cellulose. Food was restricted to maintain rats at 90% of their free feeding weight.
The colony room was maintained on a daily 6:00 a.m. lights on to 6:00 p.m. lights off cycle; the experiment was conducted during the light cycle. These protocols were approved by the University of Nebraska-Lincoln Institutional Animal Care and Use Committee.
Apparatus
Ten conditioning chambers (ENV-008CT; Med Associates, Georgia, VT, USA) measuring 30.5 × 24.1 × 21.0 cm and enclosed in sound-attenuating cubicles were utilized in this study. A variablespeed syringe pump (PMH-100VS; Med-Associates) was located outside each cubicle. A catheter port on the back of the rat was attached to the pump syringe via Tygon ® tubing threaded through a leash and out of the cubicle. A recessed receptacle (5.2 × 5.2 × 3.8 cm) fitted with a dipper arm (0.1 ml) was centered on one sidewall of each chamber. Two retractable levers were located on each side of the receptacle. A white cue light (2.54-cm diameter; 28 V, 100-mA) was mounted 7 cm above each lever and a house light (two white 28 V, 100-mA lamps; 10 cm above chamber ceiling) was located in the cubicle. An infrared emitter/detector unit was located 4 cm above the rod floor and 14.5 cm from the side wall containing the receptacle. Chamber activity was measured by the number of times this beam was broken.
Drugs
(+)-Methamphetamine hydrochloride (Sigma-Aldrich; St. Louis, MO, USA) was dissolved in 0.9% sterile saline and infused intravenously (IV) at 35.74 l over 1 s at 0.043 mg/kg/infusion. Varenicline tartrate was generously provided by NIDA (RTI, Research Triangle Park, NC, USA), dissolved in 0.9% saline, and injected intraperitoneal (IP) at 1 ml/kg. Meth during drug-primed reinstatement was also administered IP at 1 ml/kg. All doses are reported as salt weight.
Preliminaries and surgery
Preliminary training with the levers, indwelling jugular catheters surgery and subsequent variable ratio 3 (VR3) training with sucrose reinforcement was conducted using our labs standard protocol detailed in Pittenger et al. [18] . Two rats were excluded from the study for non-patent catheters.
Self-administration
Rats were assigned into 2 groups: meth self-administration (n = 7) or saline self-administration (n = 6). Self-administration sessions (2 h) were conducted daily for 19 consecutive days. Active lever pressing (VR3; active vs inactive lever randomly assigned) initiated an infusion of meth or saline depending on group, retraction of both levers, and illumination of the house light for a 20 s timeout. Both levers were extended and the house light was turned off following the timeout. Inactive lever responding was recorded but had no programed outcome.
Effects of varenicline on self-administration
Varenicline [0.0 (saline), 0.3, 1, and 3 mg/kg] was administered IP 20 min before the start of a self-administration session. Testing order of doses was pseudo-randomly assigned via a Latin-square design (i.e., all rats received all doses). Varenicline tests days were separated by 2 standard self-administration sessions to monitor deviations from baseline responding calculated as the average of the last 2 self-administration sessions before starting this test phase. No rat reached criteria for exclusion from testing; >20% variance in active lever presses or <80% of baseline responding. After varenicline testing, 2 additional self-administration sessions were given to verify stable responding before starting the extinction phase.
Extinction
This phase began 24 h after the last self-administration session. The 15 daily extinction sessions were identical to the self-administration sessions except meth and saline were no longer available for active lever pressing.
Effects of varenicline on meth-primed reinstatement
The effect of varenicline pretreatment [0.0 (saline), 0.3, 1, and 3 mg/kg] on meth-primed reinstatement was tested over 4 consecutive days. Assigned dose of varenicline, pseudo-randomly assigned via a Latin-square design, was administered 20 min before the start of the session. The meth-trigger (0.3 mg/kg) was administered 15 min before the session began. Reinstatement sessions were identical to extinction session except they were shortened to 70 min. Session length was truncated as unpublished data in our lab revealed most responding evoked by a meth-prime occurred within the first 70 min of a reinstatement session.
Data analyses
Analyses of active lever pressing and locomotor activity during the self-administration and the extinction phase were performed using two-factor ANOVAs with Group (meth vs saline) as a between-subjects factor and Sessions as a within-subjects factor. Data from both varenicline test phases were analyzed using twofactor ANOVAs with Group as a between-subjects factor and Dose as a within-subjects factor. For all analyses, significant main effects or interactions were followed by post-hoc pairwise comparisons. All pairwise comparisons employed the Holm-Bonferroni method for controlling the family-wise error rate with significance set at p < 0.05 [13] .
Results
Self-Administration
For active lever-pressing (Fig. 1A . Post-hoc analyses on the interaction revealed significantly higher active lever-pressing in meth selfadministration rats than saline self-administration rats during all but the first session (ps ≤ 0.039). Session 1 responding was higher than all but sessions 15 and 17 in the saline self-administration group (ps ≤ 0.032); no other effects of Session were observed within the meth or saline group (ps ≥ 0.078). For inactive leverpressing (data not shown), there was a main effect of Session [F(18,198) = 7.73; p < 0.001]. Inactive lever-pressing was signifi- Fig. 1 . A. Active lever presses (mean ± SEM) during self-administration sessions for the meth and saline groups. B. General locomotor activtiy during self-administration sessions for the meth and saline groups. * denotes significant differences between the meth and saline groups. cantly higher on session 1 than all other sessions (ps < 0.001), with no other effects of Session were detected.
For locomotor activity during self-administration (Fig. 1B) , there was a main effect of Drug [F(1,11) = 6.61; p = 0.026] and a Drug * Session interaction [F(1198) = 2.00; p = 0.012]. Locomotor activity in the meth self-administration group was higher than the saline self-administration group on session 18 (p = 0.029), but not on any other session (ps ≥ 0.249).
Effects of varenicline on self-administration
For active lever-pressing ( Fig. 2A) , there was only a significant main effect of Drug [F(1,11) = 9.61; p = 0.010]. This data pattern indicates that varenicline did not alter self-administration of meth or saline. No significant main effects or interactions were detected for inactive lever-pressing or locomotor activity.
Extinction
For active lever-pressing (Fig. 3A) , there was a significant main effect of Session [F(14,154) = 2.85; p < 0.001] and a Drug * Session interaction [F(12,154) = 3.68; p < 0.001]. Active lever-pressing in the meth self-administration group was higher than the saline self-administration group only for the first extinction session (p < 0.001). For inactive lever-pressing, only the main effect of Session [F(14,154) = 4.19; p < 0.001] was significant. Overall, inactive lever-pressing on session 1 was higher than all but session 3 (ps ≤ 0.002). Analysis of locomotor activity (Fig. 3B ) during extinction found no significant main effects but there was a significant Drug * Session interaction [F(14,154) = 1.77; p = 0.048]. Although the interaction was significant, there were no significant differences in activity between the meth and the saline group (ps ≥ 0.214).
Fig. 2.
A. Active lever presses (mean ± SEM) during self-administration following treatment with varenicline for the meth and saline groups. B. General locomotor activtiy during self-administration following treatment with vareniclie for the meth and saline groups. * denotes significant differences between the meth and saline groups. Fig. 3 . A. Active lever presses (mean ± SEM) during extinction sessions for the meth and saline groups. B. General locomotor activtiy during extinction sessions for the meth and saline groups. * denotes significant differences between the meth and saline groups. 
Effects of varenicline on meth-primed reinstatement
For active lever-pressing (Fig. 4A) , there was only a main effect of Varenicline Dose [F(3,33) = 6.71; p = 0.001]. This main effect reflected higher responding after pretreatment with 0.3 and 1.0 mg/kg varenicline than either saline (vehicle) or 3.0 mg/kg (ps ≤ 0.017). That is, following 0.3 and 1.0 mg/kg varenicline treatment, rats with or without a history of meth self-administration actually showed greater active lever pressing (i.e., reinstatement behavior). Likewise, there was only a main effect of Varenicline Dose [F(3,33) = 6.33; p = 0.002] for locomotor activity (Fig. 4B) . There was significantly higher locomotor activity after pretreatment with 0.3 and 1.0 mg/kg varenicline relative to saline (vehicle; ps ≤ 0.004). No effects were detected on inactive lever-pressing.
Discussion
Some research has reported that varenicline decreases selfadministration of nicotine, ethanol, and cocaine. However, other investigators have reported increases in ethanol and cocaine intake, as well as no effect with varenicline pretreatment; for a minireview of the effects of varenicline on nicotine, ethanol, and cocaine self-administration and reinstatement see Pittenger et al. [18] . In the study presented herein, varenicline did not alter methamphetamine self-administration. The inability of varenicline to alter meth-taking behavior in male rats is similar to findings with female rats in that there were no specific effects of varenicline on meth self-administration in either sex [18] . In the female rats, there was a non-specific effect of varenicline slightly reducing responding in both the saline and meth groups. This reduction was not seen in the males. The variation may be a result of inherent differences between males and females. Indeed, studies have identified meth self-administration differences between males and females [19, 21] . Future work programmatically examining possible sex differences in varenicline treatment of meth dependence would be needed to further elucidate the mechanism of these differences.
In this study, responding during the meth-primed reinstatement tests was increased by pretreatment with 0.3 and 1.0 mg/kg varenicline regardless of whether rats had a history of meth or saline self-administration. A similar non-specific enhancement was reported in female rats [18] . The increase in general locomotor activity following administration of both 0.3 and 1.0 mg/kg varenicline may suggest possible non-specific activation resulting in increased responding. This account, however, is largely discredited by the lack of altered responding on the inactive lever following administration of these doses of varenicline.
There are at least two other explanations for the non-specific enhancement of active lever pressing induced by varenicline in this study. First, varenicline may be substituting for meth, effectively increasing the dose of meth utilized as a drug-prime during the reinstatement tests. Indeed, varenicline has been shown to partially substitute for the discriminative-stimulus effects of meth [9] . Additionally, the level of responding evoked by meth in a reinstatement test is sensitive to the dose [1, 19] . The finding that 3.0 mg/kg varenicline had no effect may reflect a summative meth-like dose (i.e., varenicline + meth) that is on the descending portion of the meth-prime reinstatement curve.
The second possible explanation is that varenicline may be functioning to enhance other mildly reinforcing stimuli associated with active-lever responding. Recall that timeout stimuli including illumination of the house light and lever retraction were present throughout the experiment. Previous research has clearly shown that nicotine can enhance weakly reinforcing sensory stimuli [11, 4] . More recently, this enhancement effect has been demonstrated with other nAChR agonists including varenicline [2, 22] . This account is supported by varenicline enhancing responding not only in the meth self-administration group, but also in the saline group with responding presumably maintained by the weakly reinforcing sensory stimuli of the timeout period. This increase in reinstatement susceptibility does not appear to be an irregularity of our protocol. Increased responding during meth-primed reinstatement is concordant with reinstatement findings of other drugs of abuse including nicotine [14, 24] and cocaine [12] . Enhancement of responding is not ubiquitous. Other investigators have found no effect or a reduction in drug reinstatement and the reasons for such difference are not clear [for a summary of the literature see Pittenger et al. [18] ].
The results reported herein do not suggest varenicline would be a suitable pharmacotherapy in males, synonymous with our previous finding in females [18] . Varenicline up to 3.0 mg/kg did not decrease self-administration of meth. Further, active lever responding was increased during the meth-primed reinstatement with 0.3 and 1.0 mg/kg varenicline. An increase in reinstatement behavior is particularly notable, given the importance relapse plays in meth-use disorders [3] . That is, varenicline may actually heighten vulnerability to meth relapse in males (reported herein) and females [18] .
